Back to top
more

QIAGEN (QGEN)

(Delayed Data from NYSE)

$36.95 USD

36.95
1,964,098

+0.37 (1.01%)

Updated Jun 18, 2026 04:00 PM ET

After-Market: $36.96 +0.01 (0.03%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.00%
2Buy18.14%
3Hold10.18%
4Sell5.72%
5Strong Sell3.11%
S&P50011.49%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

4-Sell of 5       4  

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

  • Value Score A
  • Growth Score A
  • Momentum Score A
  • VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

C Value D Growth A Momentum D VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Bottom 40% (149 out of 247)

Industry: Medical - Biomedical and Genetics

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Zacks News

Zacks Equity Research

Teleflex's (TFX) Q1 Earnings Top Estimates, Margins Down

by Zacks Equity Research

Teleflex (TFX) exhibits year-over-year growth across the Americas, EMEA and Asia regions at CER in the first quarter.

Zacks Equity Research

Accuray (ARAY) Q3 Earnings Beat Estimates, Revenues Lag

by Zacks Equity Research

Despite strong product demand, Accuray (ARAY) reports an overall soft Q3 performance.

Zacks Equity Research

Bio-Rad (BIO) Q1 Earnings Surpass Estimates, Margins Up

by Zacks Equity Research

Bio-Rad's (BIO) first-quarter 2022 revenues decline year over year due to lower COVID-related demand.

Zacks Equity Research

QIAGEN (QGEN) Q1 Earnings Surpass Estimates, 2022 View Up

by Zacks Equity Research

QIAGEN (QGEN) exited first-quarter 2022 with better-than-expected results on strength in the non-COVID product portfolio driving the top line.

Zacks Equity Research

Stryker (SYK) Q1 Earnings and Revenues Surpass Estimates

by Zacks Equity Research

Stryker's (SYK) first-quarter earnings reflect strong performance across its segments.

Zacks Equity Research

DexCom (DXCM) Q1 Earnings Miss, Revenues Beat Estimates

by Zacks Equity Research

Despite a decline in bottom line, DexCom's (DXCM) first-quarter results benefit from domestic and international revenue growth and solid new customer additions.

Zacks Equity Research

Merit Medical (MMSI) Q1 Earnings Beat, FY22 View Unchanged

by Zacks Equity Research

Merit Medical (MMSI), in the first quarter, benefits from revenue growth in both its segments and from all of the product categories within its Cardiovascular unit.

Zacks Equity Research

Thermo Fisher (TMO) Q1 Earnings Beat Estimates, Margins Down

by Zacks Equity Research

The robust year-over-year revenue growth across Thermo Fisher's (TMO) Analytical Instruments and the Laboratory Products and Biopharma Services segments appears promising.

Zacks Equity Research

Baxter (BAX) Q1 Earnings and Revenues Surpass Estimates

by Zacks Equity Research

Baxter's (BAX) first-quarter results reflect robust performance across four of its business units.

Zacks Equity Research

West Pharmaceutical (WST) Q1 Earnings Top Estimates, Revenues Lag

by Zacks Equity Research

West Pharmaceutical's (WST) first-quarter earnings reflect strength in the Proprietary Products segment and operating margin expansion.